View : 61 Download: 4

Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial

Title
Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial
Authors
Choi, In AhBaek, Han-JooCho, Chul-SooLee, Yeon-AhChung, Won TaePark, Young EunLee, Yun JongPark, Yong-BeomLee, JisooLee, Shin-SeokYoo, Wan-HeeSong, Jung-SooKang, Seong WookKim, Hyun AhSong, Yeong Wook
Ewha Authors
이지수
SCOPUS Author ID
이지수scopus
Issue Date
2014
Journal Title
BMC MUSCULOSKELETAL DISORDERS
ISSN
1471-2474JCR Link
Citation
vol. 15
Keywords
Rheumatoid arthritisPelubiprofenCelecoxibNon-inferiority
Publisher
BIOMED CENTRAL LTD
Indexed
SCIE; SCOPUS WOS
Abstract
Background: Pelubiprofen is a prodrug of 2-arylpropionic acid with relatively selective effects on cyclooxygenase-2 activity. The aim of this study was to compare the efficacy and safety profiles of pelubiprofen with those of celecoxib in patients with rheumatoid arthritis. Methods: This was a 6-week, multicenter, randomized, double-blind, double- dummy, parallel-group, phase III, non-inferiority clinical trial. The primary end point was non-inferiority of pain decrease from baseline to week-6 as determined using a 100 mm pain visual analog scale (VAS). Pelubiprofen was considered non-inferior to celecoxib if the lower limit of the 97.5% confidence interval for treatment difference [(pain reduction in pelubiprofen group) - (pain reduction in celecoxib group)] was more than - 10 mm. The secondary end points were as follows: non-inferiority of (1) reduction of Korean health assessment questionnaire (KHAQ) score; (2) decreased duration of morning stiffness; and (3) decrease in the frequency and total dose of rescue drugs after 6 weeks of treatment. Results: Seventy-seven patients in the pelubiprofen group and 68 patients in the celecoxib group started the study medication. Pelubiprofen was non-inferior to celecoxib with regard to reduction in VAS pain severity (difference, mean +/- SD 5.0 +/- 20.1; 97.5% CI, -2.3 to 8). Pelubiprofen was also non-inferior to celecoxib in terms of the secondary end points, such as, decrease in KHAQ score (0.0 +/- 0.5, 97.5% CI -0.2 to 8), decrease in duration of morning stiffness (median 0.0 minute in both groups), and decrease in the frequency (0.7 +/- 3.5, 97.5% CI -0.6 to 8) and total amount (0.7 +/- 3.6, 97.5% CI - 0.6 to 8) of rescue medication uses during the 6 week study period. Safety analysis revealed 31.2% patients in the pelubiprofen group and 20.6% patients in the celecoxib group experienced an adverse drug reaction (ADR). The frequency of gastrointestinal ADRs was 20.8 % and 8.8%, respectively. Conclusions: Pelubiprofen was found to be as effective as celecoxib at pain reduction and for relieving stiffness in RA patients. However, more patients in the pelubiprofen group experienced ADR and the frequency of gastrointestinal ADRs was higher in the pelubiprofen group.
DOI
10.1186/1471-2474-15-375
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
001.pdf(478.97 kB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE